Antireflux Mucosal Ablation Safe, Effective for Refractory Reflux Disease
By Lori Solomon HealthDay Reporter
MONDAY, Nov. 6, 2023 -- Antireflux mucosal ablation (ARMA) cuts short-term gastroesophageal reflux disease (GERD) symptoms in two-thirds of patients undergoing the endoscopic treatment, according to a study published online Oct. 3 in the Journal of Gastroenterology and Hepatology.
Yuto Shimamura, M.D., from Showa University in Tokyo, and colleagues evaluated the feasibility, safety, and effectiveness of ARMA. The analysis included 68 patients with GERD symptoms refractory to acid suppression medications or those dependent on such medications.
The researchers found that clinical success rates (defined as >50 percent reduction in a validated GERD questionnaire) at two to six months and one year post-ARMA were 60 and 70 percent, respectively. There were significant improvements seen in the median GERD health-related quality of life score from 26 to 11 at two to six months. Among those who underwent 24-hour pH monitoring (51 patients), median acid exposure time significantly decreased from 5.3 to 0.7 percent, along with a significant reduction in esophagitis rates. No factors predicted short-term success in a multivariate analysis. Transient stenosis requiring balloon dilation was seen in nine patients (13.2 percent).
"Both reflux hypersensitivity and confirmed GERD patients, regardless of their response to acid suppression medication, may be suitable candidates," the authors write.
Several authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Novel Score Validated for Diagnosis of Gastroesophageal Reflux Disease
MONDAY, May 6, 2024 -- A novel high-resolution manometry (HRM) score can stratify the risk and severity of gastroesophageal reflux disease (GERD), according to a study published...
Use of Acid-Suppression Therapy Linked to Migraine, Severe Headache
FRIDAY, April 26, 2024 -- Use of acid-suppression therapy is associated with higher odds of migraine or severe headache, according to a study published online April 24 in...
Anxiety, Depression Associated With Gastroesophageal Reflux Disease
TUESDAY, April 2, 2024 -- Anxiety and depression are associated with an increased incidence of gastroesophageal reflux disease (GERD), according to a study published online March...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.